Industry Overview

PET-CT market was valued at $2.4 billion in 2025 and is projected to reach $3.5 billion by 2035, growing at a CAGR of 4.0% during the forecast Period (2026-2035). The market is growing due to the rising prevalence of chronic diseases, an aging population, and the increasing demand for advanced diagnostic tools. Key factors include technological advancements in PET-CT scanners, increased awareness of early disease detection, and higher healthcare expenditure in emerging economies. Challenges include the high cost of devices and the limited shelf-life and supply of some radiopharmaceuticals.

Market Dynamics

Rising Global Cancer Incidence & Expanding Clinical Applications

The foremost driver of the global PET-CT market is the rapidly increasing burden of cancer worldwide, which has significantly expanded the demand for advanced diagnostic imaging. PET-CT has become the gold standard for tumor detection, staging, treatment planning, and therapy response assessment. As cancer screening programs strengthen across North America, Europe, China, and India, the number of PET-CT procedures continues to rise steadily. Beyond oncology, PET-CT is gaining clinical traction in cardiology for myocardial viability assessment and in neurology for early evaluation of Alzheimer’s disease and other neurodegenerative disorders. This expansion into multi-specialty applications broadens the overall patient pool, increasing installation rates and recurring scan volumes across hospitals and imaging centers.

Technological Advancements in Digital PET & AI-Enhanced Imaging

Rapid technological innovation is also propelling market growth, especially the global shift toward digital PET-CT systems, which offer superior sensitivity, improved time-of-flight resolution, reduced radiation dose, and faster acquisition times. Digital photon-counting detectors, advanced silicon photomultipliers (SiPMs), and AI-powered image reconstruction algorithms have collectively enhanced diagnostic accuracy while increasing workflow efficiency. Hospitals and diagnostic centers are increasingly adopting these next-generation systems to handle higher patient throughput and achieve better clinical outcomes. Additionally, AI-driven automation tools for segmentation, reporting, and noise reduction are making PET-CT more efficient for radiologists, further accelerating replacement cycles in mature markets and adoption in emerging regions.

Growth in Radiopharmaceutical Supply & Theranostics Expansion

A strong rise in the availability and diversity of radiopharmaceuticals, particularly F-18 and Ga-68 labeled tracers, continues to fuel PET-CT utilization globally. The growing popularity of theranostics, which combines molecular imaging with targeted radioligand therapy (RLT), is also transforming the PET-CT ecosystem. As new radiotracers enter clinical use for prostate cancer, neuroendocrine tumors, and other oncological conditions, the need for PET-CT systems increases in parallel. Investments in cyclotrons, radiopharmacies, and global radiotracer distribution networks have significantly improved tracer accessibility, especially in APAC and Europe. This enhanced supply chain drives higher procedure volumes and encourages hospitals and private imaging centres to install new PET-CT units to support expanding clinical pathways.

Market Segmentation

• Based on the product type, the market is segmented into a stationary scanner and a portable scanner.
• Based on the application, the market is segmented into oncology, neurology, cardiology, and others.
• Based on the end user, the market is segmented into hospitals, diagnostic clinics, and others.

Hospitals to Grow at a Considerable Market Share

Among all segments, hospitals dominate the global PET-CT market as the largest segment, driven by their extensive adoption of advanced imaging infrastructure, higher patient inflow, and ability to perform high-complexity diagnostic procedures. Hospitals serve as the primary hubs for oncology, cardiology, and neurology diagnostics, three major clinical areas that rely heavily on PET-CT imaging for early disease detection, staging, treatment planning, and therapy monitoring. Their strong capital budgets enable rapid integration of next-generation PET-CT systems, including digital and time-of-flight technologies, which enhance imaging accuracy and operational efficiency.

Additionally, hospitals often participate in multidisciplinary care programs and clinical trials, further boosting PET-CT utilization. The growing burden of cancer cases, rising demand for precision diagnostics, and expanding reimbursement support across major markets continue to position hospitals as the leading end-user segment, contributing the largest share to the global PET-CT market.

Oncology: A Key Segment in Market Growth

Among all product and application segments in the PET-CT market, Oncology continues to be the dominant and fastest-growing segment, driving the majority of market expansion globally. This strong growth is primarily attributed to the rising prevalence of cancer, increasing adoption of early and accurate diagnostic tools, and expanding applications of PET-CT scans in staging, restaging, treatment planning, and monitoring therapeutic response.

Oncology accounts for the largest share because PET-CT provides superior metabolic and anatomical imaging, making it indispensable in detecting tumors, assessing metastasis, and guiding precision therapies. The rising demand for targeted therapies and immunotherapies further boosts the need for advanced imaging to evaluate treatment effectiveness, driving continuous utilization of PET-CT systems in cancer care.

Additionally, advancements in radiotracers, such as FDG and novel oncology-specific tracers, enhance sensitivity and expand use cases across a broad spectrum of cancers. Growth is also supported by increasing investments in cancer screening programs, especially in developed markets, along with improving access to diagnostic infrastructure in emerging economies. Hospitals, cancer centers, and diagnostic imaging networks are rapidly upgrading and expanding their PET-CT capabilities, reinforcing oncology’s position as the key segment shaping overall PET-CT market growth.

Regional Outlook

The global PET-CT market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global PET-CT market with the largest share, driven by its advanced healthcare infrastructure, high adoption of cutting-edge diagnostic imaging technologies, and strong presence of leading imaging system manufacturers. The country has a significantly higher installation base of PET-CT scanners compared to other regions, supported by substantial healthcare spending, strong reimbursement frameworks, and continuous upgrades of imaging facilities. The rapid integration of hybrid imaging technologies, such as digital PET-CT and time-of-flight systems, further strengthens the US position. Moreover, the nation’s high cancer burden and increasing use of PET-CT in oncology for early diagnosis, staging, and therapy monitoring contribute heavily to market demand.

The US is also at the forefront of radiotracer innovations, with robust R&D activities, well-established cyclotron networks, and regulatory approvals that accelerate clinical use of novel tracers. Academic medical centers and leading cancer institute’s continuously adopt next-generation systems, reinforcing market leadership. Additionally, strategic collaborations between imaging technology companies, radiopharmaceutical manufacturers, and healthcare providers support constant innovation and rapid deployment of advanced PET-CT solutions, ensuring that the United States remains the dominant country in the global PET-CT market.

Market Players Outlook

The major companies operating in the global PET-CT market include Canon Medical Systems Corp., FUJIFILM Corp., GE HealthCare, Koninklijke Philips N.V., Siemens Healthineers, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Developments

• In March 2025, Jordan inaugurated its first advanced nuclear medicine diagnostic center in a public hospital, supported by the IAEA. This initiative increases access to cancer diagnostic services. Through the IAEA's Rays of Hope initiative, PET-CT equipment was provided to enhance early detection and cancer management. The PET-CT technology utilizes radioactive glucose to create detailed images, enabling the identification of potential cancer growths or infections.
• In May 2025, Mahajan Imaging launched North India’s first 128-Slice Digital PET-CT scanner, the Omni Legend by GE HealthCare, along with a modern pathology lab in Gurugram. This facility enhances integrated cancer care and precision diagnostics in the Delhi NCR region. The AI-powered scanner provides a spatial resolution of 1.4mm, ensuring earlier cancer detection, superior image quality, and a 60% reduction in radiation exposure. Designed for patient comfort, the facility features streamlined workflows and a friendly atmosphere to enhance the diagnostic experience.
• In June 2024, Siemens unveiled its latest PET/CT scanner, the Biograph Trinion, on June 9 at the Society of Nuclear Medicine and Molecular Imaging meeting. Recently cleared by the FDA, it features a scalable field-of-view design allowing on-site upgrades without extensive renovations. The scanner uses lutetium oxyorthosilicate (LSO) crystal elements for high spatial resolution and ultrafast time-of-flight performance of 239 picoseconds, enhancing small lesion detectability and sensitivity. It also includes a user-friendly air-cooled digital detector and is energy-efficient, with a power-save mode that can save up to 46% energy overnight.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global PET-CT market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.